Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore how advanced liquid biopsy and gene expression analysis from RGCC are transforming cancer detection at the earliest stages—including stage ZERO.
Dr. Papasotiriou discusses his personal motivation, the clinical power of Oncotrace and Onco-D-clare testing, and actual patient outcomes from RGCC's approach—including doubled survival rates in advanced cancer cases.
Learn about:




Our scientists use world-leading technology, equipment, and innovative techniques to develop a range of cancer screening and monitoring tests. Our tests help cancer patients and their healthcare professionals get a comprehensive but personalized view of each patient’s genetics, physiology, and immune profiles.
We believe this level of detail is crucial in developing an individualized care plan for every patient struggling with cancer. We aim to provide a unique insight into every patient’s cancer biology to empower them about what treatment modalities are ideal for bringing them success in their cancer journey!
Reach out to us to start your journey to empowering information for your cancer treatment today by contacting us online.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.






















